Mucormycosis-A serious threat in the COVID-19 pandemic?

Szarpak, Lukasz; Chirico, Francesco; Pruc, Michal; Szarpak, Luiza; Dzieciatkowski, Tomasz; Rafique, Zubaid

Szarpak, Lukasz; Chirico, Francesco; Pruc, Michal; Szarpak, Luiza; Dzieciatkowski, Tomasz; Rafique, Zubaid.

Szarpak L; Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland; Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland.
Chirico F; Post-graduate School of Occupational Health, Università Cattolica del Sacro Cuore, Rome, Italy; Health Service Department, Italian State Police, Milan, Italy.
Pruc M; Polish Society of Disaster Medicine, Warsaw, Poland.
Szarpak L; Polish Society of Disaster Medicine, Warsaw, Poland; Polonia University, Czestochowa, Poland.
Dzieciatkowski T; Chair and Department of Medical Microbiology, Medical University of Warsaw, Warsaw, Poland.
Rafique Z; Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA.

J Infect ; 83(2): 237-279, 2021 08.

Article in English | MEDLINE | ID: covidwho-1240447

Subject(s)

COVID-19; Mucormycosis; Antifungal Agents/therapeutic use; Humans; Mucormycosis/diagnosis; Mucormycosis/drug therapy; Mucormycosis/epidemiology; Pandemics; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Mucormycosis Type of study: Diagnostic study / Observational study Limits: Humans Language: English Journal: J Infect Year: 2021 Document Type: Article Affiliation country: J.jinf.2021.05.015

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google